307 related articles for article (PubMed ID: 20048054)
1. FKBP51 promotes assembly of the Hsp90 chaperone complex and regulates androgen receptor signaling in prostate cancer cells.
Ni L; Yang CS; Gioeli D; Frierson H; Toft DO; Paschal BM
Mol Cell Biol; 2010 Mar; 30(5):1243-53. PubMed ID: 20048054
[TBL] [Abstract][Full Text] [Related]
2. Role of the HSP90-associated cochaperone p23 in enhancing activity of the androgen receptor and significance for prostate cancer.
Reebye V; Querol Cano L; Lavery DN; Brooke GN; Powell SM; Chotai D; Walker MM; Whitaker HC; Wait R; Hurst HC; Bevan CL
Mol Endocrinol; 2012 Oct; 26(10):1694-706. PubMed ID: 22899854
[TBL] [Abstract][Full Text] [Related]
3. The co-chaperone p23 promotes prostate cancer motility and metastasis.
Cano LQ; Lavery DN; Sin S; Spanjaard E; Brooke GN; Tilman JD; Abroaf A; Gaughan L; Robson CN; Heer R; Mauri F; de Rooij J; Driouch K; Bevan CL
Mol Oncol; 2015 Jan; 9(1):295-308. PubMed ID: 25241147
[TBL] [Abstract][Full Text] [Related]
4. FKBP51 and Cyp40 are positive regulators of androgen-dependent prostate cancer cell growth and the targets of FK506 and cyclosporin A.
Periyasamy S; Hinds T; Shemshedini L; Shou W; Sanchez ER
Oncogene; 2010 Mar; 29(11):1691-701. PubMed ID: 20023700
[TBL] [Abstract][Full Text] [Related]
5. Androgen mediated regulation and functional implications of fkbp51 expression in prostate cancer.
Febbo PG; Lowenberg M; Thorner AR; Brown M; Loda M; Golub TR
J Urol; 2005 May; 173(5):1772-7. PubMed ID: 15821585
[TBL] [Abstract][Full Text] [Related]
6. Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells.
De Leon JT; Iwai A; Feau C; Garcia Y; Balsiger HA; Storer CL; Suro RM; Garza KM; Lee S; Kim YS; Chen Y; Ning YM; Riggs DL; Fletterick RJ; Guy RK; Trepel JB; Neckers LM; Cox MB
Proc Natl Acad Sci U S A; 2011 Jul; 108(29):11878-83. PubMed ID: 21730179
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of stromal FK506-binding protein 1 and androgen receptor in prostate cancer outcome.
Leach DA; Trotta AP; Need EF; Risbridger GP; Taylor RA; Buchanan G
Prostate; 2017 Feb; 77(2):185-195. PubMed ID: 27718274
[TBL] [Abstract][Full Text] [Related]
8. The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells.
Saporita AJ; Ai J; Wang Z
Prostate; 2007 Apr; 67(5):509-20. PubMed ID: 17221841
[TBL] [Abstract][Full Text] [Related]
9. Essential role for Co-chaperone Fkbp52 but not Fkbp51 in androgen receptor-mediated signaling and physiology.
Yong W; Yang Z; Periyasamy S; Chen H; Yucel S; Li W; Lin LY; Wolf IM; Cohn MJ; Baskin LS; Sa Nchez ER; Shou W
J Biol Chem; 2007 Feb; 282(7):5026-5036. PubMed ID: 17142810
[TBL] [Abstract][Full Text] [Related]
10. Effect of geldanamycin on androgen receptor function and stability.
Vanaja DK; Mitchell SH; Toft DO; Young CY
Cell Stress Chaperones; 2002 Jan; 7(1):55-64. PubMed ID: 11894840
[TBL] [Abstract][Full Text] [Related]
11. Long-range activation of FKBP51 transcription by the androgen receptor via distal intronic enhancers.
Makkonen H; Kauhanen M; Paakinaho V; Jääskeläinen T; Palvimo JJ
Nucleic Acids Res; 2009 Jul; 37(12):4135-48. PubMed ID: 19433513
[TBL] [Abstract][Full Text] [Related]
12. The immunophilin ligands cyclosporin A and FK506 suppress prostate cancer cell growth by androgen receptor-dependent and -independent mechanisms.
Periyasamy S; Warrier M; Tillekeratne MP; Shou W; Sanchez ER
Endocrinology; 2007 Oct; 148(10):4716-26. PubMed ID: 17615153
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Targeting of the FKBP52 Co-Chaperone in Steroid Hormone Receptor-Regulated Physiology and Disease.
Guy NC; Garcia YA; Cox MB
Curr Mol Pharmacol; 2015; 9(2):109-25. PubMed ID: 25986565
[TBL] [Abstract][Full Text] [Related]
14. FKBP51 and FKBP52 regulate androgen receptor dimerization and proliferation in prostate cancer cells.
Maeda K; Habara M; Kawaguchi M; Matsumoto H; Hanaki S; Masaki T; Sato Y; Matsuyama H; Kunieda K; Nakagawa H; Shimada M
Mol Oncol; 2022 Feb; 16(4):940-956. PubMed ID: 34057812
[TBL] [Abstract][Full Text] [Related]
15. Prostaglandin 15d-PGJ(2) inhibits androgen receptor signaling in prostate cancer cells.
Kaikkonen S; Paakinaho V; Sutinen P; Levonen AL; Palvimo JJ
Mol Endocrinol; 2013 Feb; 27(2):212-23. PubMed ID: 23192983
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of ID4 promotes a CRPC phenotype with constitutive AR activation through FKBP52.
Joshi JB; Patel D; Morton DJ; Sharma P; Zou J; Hewa Bostanthirige D; Gorantla Y; Nagappan P; Komaragiri SK; Sivils JC; Xie H; Palaniappan R; Wang G; Cox MB; Chaudhary J
Mol Oncol; 2017 Apr; 11(4):337-357. PubMed ID: 28252832
[TBL] [Abstract][Full Text] [Related]
17. Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha.
Buchanan G; Ricciardelli C; Harris JM; Prescott J; Yu ZC; Jia L; Butler LM; Marshall VR; Scher HI; Gerald WL; Coetzee GA; Tilley WD
Cancer Res; 2007 Oct; 67(20):10087-96. PubMed ID: 17942943
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression.
Shafi AA; Cox MB; Weigel NL
Steroids; 2013 Jun; 78(6):548-54. PubMed ID: 23380368
[TBL] [Abstract][Full Text] [Related]
19. Paired box 2 upregulates androgen receptor gene expression in androgen-independent prostate cancer.
Ito S; Ueda T; Ueno A; Nakagawa H; Taniguchi H; Hongo F; Kamoi K; Okihara K; Kawauchi A; Miki T
FEBS J; 2014 Oct; 281(19):4506-18. PubMed ID: 25132193
[TBL] [Abstract][Full Text] [Related]
20. The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression.
Verras M; Lee J; Xue H; Li TH; Wang Y; Sun Z
Cancer Res; 2007 Feb; 67(3):967-75. PubMed ID: 17283128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
